Beijing Correspondent, China
Based in Beijing, Zhuang Pinghui joined the Post in 2004 to report on China. She covers a range of issues including policy, healthcare, culture and society.
Latest from Zhuang Pinghui
Even though the risk is low, researchers say Covid-19 prevention measures should include strict scrutiny of imported frozen goods.
Kashgar in Xinjiang orders residents to stay in their own neighbourhoods while citywide tests are carried out.
A number of Chinese cities have carried out mass tests, but Wu Zunyou from the China Centre for Disease Control and Prevention says localised tests are enough.
Drug, sold under the brand name Veklury, approved for hospital use in adults and children aged 12 and above.
Adding its weight to the WHO-led alliance could safeguard China’s own access to vaccines and aid acceptance of those produced in China after past scandals.
State-owned China National Biotec Group says it will provide its two vaccine candidates for free to those who register online, even though they are still going through clinical trials.
But a free immunisation programme could still be covered by government funds, according to expert.
Qingdao authorities say testing programme under way and should be completed within five days.
The clash between Miami Heat and the LA Lakers was the first game shown by CCTV for over a year after a team boss expressed support for the Hong Kong protests.
‘My arm went blue from drawing blood dozens of times,’ China National Biotec Group vice-president says after execs took jabs before human trials were approved.
Millions of cadres from government and state enterprises have been sent to impoverished areas to help raise incomes over the last few years.
Executive from China National Biotec Group, one of the companies aiming to develop the first approved vaccine, blames ‘hostile relations and US smearing’.
Poverty alleviation in Liangshan hinges largely on schooling measures and the belief education is key to stopping poverty passing to the next generation.
Despite the expense and resources spent on improving the lives of poor rural Chinese, there is more to be done to help them adjust and keep them in work.
Commission for Discipline Inspection says it will go after money sent overseas days after Canada-based singer says she still hopes for justice.
Zheng Zhongwei from the National Health Commission says WHO standards were used as a guide to administer shots despite ongoing phase 3 trials.
China National Biotec Group is applying for conditional regulatory approval to start universal vaccination programme.
Interim trial data suggests the experimental treatment has ‘a direct antiviral effect’ on patients with mild and moderate symptoms, according to company.
Two Myanmese in Ruili test positive, prompting authorities to crack down on illegal entrants and put restrictions on the jade trade.
An official from China National Biotec Group says the evidence from an emergency use scheme suggests the products are working.
Exercises are the latest in a string of manoeuvres Beijing has made public this month.
Entertainment firm Yue Hua says it has been punished by authorities in China over the performance, without giving further details.
Public health experts warn the deadly infectious disease is silently spreading and claiming more lives, as medical resources are diverted to fight Covid-19.
Two candidates developed by state-owned China National Biotec Group are already being tested in Abu Dhabi, and will also be trialled in Bahrain.
The collapse of cooperation between Washington and Beijing is ‘very sad and a disappointment’, vice-president of Centre for China and Globalisation says during webinar.
Medical experts say rapid vaccine development is causing public anxiety but wide-scale immunisation may be the only route back to a safely reopened society.
Mayo Clinic research finds that treating patients with blood plasma containing a high level of antibodies could reduce mortality rate.
Chinese manufacturers have indispensable role in the international market, despite tougher overseas scrutiny, SCMP Research report concludes.
Wuhan Institute of Virology director dismisses conspiracy theory, saying virus sequence collected from Yunnan cave was decades away in evolution from Sars-CoV-2.
Six vaccine candidates have reached phase 3 human trials, but some may fall at this final hurdle and their success also comes down to what we expect from them.